Inhibition of T-bet-mediated transcriptional elongation as a novel therapeutic target for inflammatory bowel disease.

炎症性肠病（IBD）是一种可导致令人痛苦的症状的疾病，包括出血性腹泻，腹痛和体重减轻。IBD的并发症包括癌症、肠衰竭和需要紧急手术的肠穿孔。即使是最有效的治疗，很大一部分病人的失败反应，并继续与衰弱的症状。我们有兴趣发现更多的靶向治疗，最终可能使这些患者受益。我们认为，IBD是由免疫系统过度活跃引起的，特别是在肠道。一种名为T-bet的蛋白质在维持健康和受调节的免疫系统中起着重要作用。研究表明，一些IBD患者的T-bet活性异常，这可能导致免疫过度活跃，最终导致IBD。我们想用新的实验性治疗方法来测试阻断T-bet活性的效果，看看这是否可以治疗IBD。我们将首先治疗IBD小鼠，以确保治疗安全有效，然后研究对IBD患者结肠标本的影响。我们希望发现一种新的有效的治疗方法，可以在未来开发，测试并使患者受益。

Inflammatory bowel disease (IBD) is a condition that can lead to distressing symptoms including bloody diarrhoea, abdominal pain and weight loss. Complications of IBD include cancer, intestinal failure and bowel perforation requiring emergency surgery. Even with the most effective of treatments, a large proportion of patient's fail to respond and continue to suffer with debilitating symptoms. We are interested in discovering more targeted therapies that may ultimately benefit these patients.We believe that IBD is caused by over-activity of the immune system, particularly in the gut. A protein called T-bet plays a fundamental role in maintaining a healthy and regulated immune system. Research has shown that some patients with IBD have abnormal T-bet activity and that this may lead to immune over-activity and ultimately IBD.We would like to test the effects of blocking the activity of T-bet with new experimental treatments to see if this can treat IBD. We will initially treat mice with IBD to ensure the treatment is safe and effective before studying the effects on colonic specimens from patients with IBD. We hope to discover a new and effective treatment that can be developed, tested and benefit patients in the future.